EpCAM expression in primary adenocarcinoma of the gastrointestinal tract
| Tumour type (no. of samples) | No EpCAM overexpression* | EpCAM overexpression* | ||||||
| No expression (TIS 0) | Weak expression (TIS 1–4) | Moderate expression (TIS 6, 8) | Intense expression (TIS 9, 12) | |||||
| n | % | n | % | n | % | n | % | |
| Colon cancer (104) | 0 | 0 | 7 | 6 | 12 | 12 | 85 | 82 |
| Ampullary cancer (34) | 0 | 0 | 5 | 15 | 14 | 41 | 15 | 44 |
| Gastric cancer (73) | 3 | 4 | 16 | 22 | 14 | 19 | 40 | 55 |
| Oesophageal cancer (43) | 5 | 12 | 10 | 23 | 11 | 26 | 17 | 39 |
| Gallbladder cancer (128) | 9 | 7 | 34 | 27 | 53 | 41 | 32 | 25 |
| Pancreatic cancer (203) | 2 | 1 | 71 | 35 | 56 | 26 | 74 | 37 |
| Hepatocellular carcinoma (47) | 40 | 86 | 3 | 6 | 2 | 4 | 2 | 4 |
EpCAM expression was determined by immunohistochemistry.
↵* EpCAM overexpression defined by Gastl et al3.
EpCAM, epithelial cell adhesion molecule; TIS, total immunostaining score.